We investigated the influence of nocebo effects in clinical drug trials in fibromyalgia syndrome (FMS) and painful peripheral diabetic neuropathy (DPN) by meta-analysis.
We analyzed patient- and study- related predictors of the nocebo effect. In FMS studies, the nocebo effect accounted for 73% of the occurrence of at least one adverse events, in painful DPN for 82%. For the study discontinuation in 59% (FMS) and 44% (DPN) of the cases. The nocebo response in both deseases was associated with prolonged study period and the beginning of the study in the younger past.
«
We investigated the influence of nocebo effects in clinical drug trials in fibromyalgia syndrome (FMS) and painful peripheral diabetic neuropathy (DPN) by meta-analysis.
We analyzed patient- and study- related predictors of the nocebo effect. In FMS studies, the nocebo effect accounted for 73% of the occurrence of at least one adverse events, in painful DPN for 82%. For the study discontinuation in 59% (FMS) and 44% (DPN) of the cases. The nocebo response in both deseases was associated with pr...
»